Donate
Believe in a Cure Gala
New Family
Medical News and Alerts

Medicaid Eligibility Renewals are Coming!

February 8, 2023

Medicaid Eligibility Renewals are Coming!

Medicaid eligibility renewals were paused during the COVID-19 pandemic but are re-starting soon. This means that almost everyone on Medicaid in the US will need to renew their eligibility at some point between February 2023 and May 2024. Each state is on its own timeline.

It is very important that everyone update their contact information with their state, respond to renewal notices, and reach out for help if they lose coverage or don’t know what to do with their renewal notice. The Epilepsy Foundation 24/7 helpline is ready to assist. https://www.epilepsy.com/247-helpline

Learn More: https://www.medicaid.gov/resources-for-states/coronavirus-disease-2019-covid-19/unwinding-and-returning-regular-operations-after-covid-19/renew-your-medicaid-or-chip-coverage/index.html

Related Posts

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

by | Dec 2, 2024

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

by | Dec 12, 2023

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...

FDA Warns of Rare but Serious Drug Reaction

FDA Warns of Rare but Serious Drug Reaction

by | Dec 4, 2023

The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is...